FDA official logo
GSRS logoPFDA official logo

TRASTUZUMAB BRENGITECAN

UNII:5MHN3G4T8J
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:TRASTUZUMAB BRENGITECAN
GSRS Full Record:

  • 2761149-81-7
  • Immunoglobulin G1 [de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal BL-M07D1 γ1-chain), complex with human-Mus musculus monoclonal BL-M07D1 κ-chain, dimer, 214′′,214′′′,223,223′,229,229′,232,232′-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-β-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
  • Trastuzumab brengitecan
  • immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated to a camptothecin derivative
  • trastuzumab brengitecan [INN]



UNII - 5MHN3G4T8J | UNII Search Service